SEC Form 4 · accession 0000882104-17-000128
PDL BIOPHARMA, INC. · PDLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Peter McLaughlin
Officer — CEO
Period of report
Dec 15, 2017
Accepted (ET)
Dec 19, 2017 · 8:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Dec 15, 2017 | D | 151,678 | $0.00 | D | 1,252,785 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Disposition of common stock due to performance criteria not being achieved under equity incentive plans.